You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Moderna agreed that Chief Legal Officer Shannon Thyme Klinger will retire by March 31, 2027, with $1,628,300 in severance, COBRA support through September 30, 2028, and potential litigation payments of $2,500,000 and up to $5,500,000.
Moderna raised its 2026 revenue growth outlook to 15% to 25% from up to 10%. Its phase 3 melanoma therapy with pembrolizumab reduced recurrence or death risk by 42%, while quarterly revenue reached $1.3 billion.
Moderna reported revenue of $1,313 million and net income of $162 million for the quarter ended September 30, 2026. Nine-month net loss was $(1,963) million, and operating activities used $(2,715) million of cash.
Moderna reported third-quarter revenue of $1.3 billion and net income of $162 million, raised its 2026 revenue growth outlook to 15%–25%, and expects year-end cash and investments of approximately $8.1 billion to $8.3 billion.
Moderna appointed Juan Andres Chief Operating Officer effective October 5, 2026, to lead manufacturing and report to Stéphane Bancel. Jerh Collins will retire as Chief Technical Operations and Quality Officer.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| COVID (1) net product sales | $1.24B | FY2026 Q3 | +28.1% |
|
|
|||
| risk of distant metastasis or death | 38% | In October | — |
| risk of recurrence or death | 42% | In October | — |
| Cash, cash equivalents and investments | 6.9B | as of June 30, 2026 | — |
| International revenue | 58M | the second quarter of 2026 | — |
| royalty expenses | 11M | the three months ended June 30, 2026 filing | — |
| RSV net product sales | $3M | the three months ended June 30, 2026 filing | — |
| U.S. revenue | 87M | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRNA
this stock
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
|
ARGX
Argenx SE
|
$60.37B | +14.2% | — | — | 2.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Moderna agreed that Chief Legal Officer Shannon Thyme Klinger will retire by March 31, 2027, with $1,628,300 in severance, COBRA support through September 30, 2028, and potential litigation payments of $2,500,000 and up to $5,500,000.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRNA | -12.1% | +2.5% | +375.0% | +0.7% | +657.4% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -14.7% | +3.6% | +374.5% | +0.9% | +646.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
